Form 4: IN8BIO, INC. Insider Reports Stock Option Grant

IN8BIO, INC. CEO William Ho receives a stock option grant for 154,500 shares, with vesting scheduled over four years.

Summary

• William Ho, CEO of IN8BIO, INC., was granted an employee stock option on May 9, 2026.
• The option allows for the purchase of 154,500 shares of common stock at an exercise price of $1.58 per share.
• The option has an expiration date of May 9, 2036.
• Vesting of the shares is scheduled in four equal installments: 25% on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent upon continued service.
• This transaction is reported under Rule 10b5-1(c) for the purchase of equity securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard executive compensation practice rather than a significant operational or financial event.

Positives

• Grant of stock options to CEO indicates a commitment to long-term incentive and alignment with company performance.
• The option grant provides potential upside for the CEO, tied to the company's future stock price appreciation.
• The structured vesting schedule encourages continued service and commitment to the company's success.

Negatives

• The exercise price of $1.58 per share means the option is only profitable if the stock price increases significantly above this level.
• The vesting is contingent on continued service, meaning the CEO could forfeit unvested options if employment ceases.

Risks

• The value of the stock options is subject to market volatility and the company's future performance.
• If the company's stock price does not exceed the exercise price of $1.58, the options will expire worthless.
• The CEO's continued employment is a condition for vesting, introducing a risk of forfeiture if employment is terminated.

Future Outlook

The stock option grant implies a positive outlook for the company's stock performance, as it is designed to incentivize management to drive value appreciation above the $1.58 exercise price.

Industry Context

StockSavvy.ai notes that granting stock options to key executives is a common practice in the biotechnology sector to align leadership incentives with shareholder value creation, especially during periods of development and growth.

Stakeholder Impact

• Shareholders: The grant aligns CEO incentives with increasing shareholder value, but the dilutive effect of future share issuance upon option exercise should be considered.
• Employees: May be motivated by the CEO's long-term commitment and potential for company growth.
• Management: The CEO's compensation is directly tied to the company's stock performance.

Next Steps

• Continued service by William Ho through the specified vesting dates.
• Potential exercise of stock options if the stock price exceeds $1.58 per share.

Key Dates

Keywords

IN8BIO, INC., INAB, Form 4, Stock Option, Employee Stock Option, Beneficial Ownership, Insider Trading, CEO, William Ho, Vesting Schedule, SEC Filing